Sangamo Therapeutics Return on Equity

Sangamo Therapeutics (SGMOQ) currently reports a ROE of -468187.69%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Sangamo Therapeutics's ROE history and peer comparisons.

Sangamo Therapeutics's ROE of -468187.69% is lower than the Healthcare sector average of -100.59%. That is roughly 465349.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sangamo Therapeutics's current -468187.69% should be judged against Healthcare norms (sector average: -100.59%) and against SGMOQ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -468187.69%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Sangamo Therapeutics, and consider following SGMOQ for alerts when major investors trade the stock.

Sangamo Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -468187.69% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGMOQ with unrelated industries.